zonisamide sandoz
sandoz d.d. - zonizamidas - kietosios kapsulės - 100 mg; 25 mg; 50 mg - zonisamide
gefitinib mylan
mylan pharmaceuticals limited - gefitinibas - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - gefitinib mylan yra nurodyta kaip monotherapy gydyti suaugusiems pacientams su lokaliai išplitusio arba metastazavusio nesmulkialąstelinio plaučių vėžio (nsclc) su ijungtu mutacijas, egfr‑tk.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antinavikiniai vaistai - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
gefitinib norameda
norameda, uab - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
gefitinib krka
krka, d.d., novo mesto - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
gefitinib zentiva [gefitinib alvogen]
zentiva k.s. - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
gefitinib sandoz
sandoz d.d. - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
gefitinib teva
teva b.v. - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.